• Healthcare Realty Trust Incorporated has reported past fourth-quarter 2025 results showing revenue of US$286.3 million and net income of US$14.39 million, alongside 2026 EPS guidance between a loss of US$0.05 and a profit of US$0.05 and approval of a US$0.24 per-share dividend payable in March 2026.
• Management highlighted that 2025 was a transformational year, with a revamped asset management platform, US$1.20 billion of asset sales exiting 14 non-core markets, improved leasing performance, and the launch of a US$600 million commercial paper program to support future corporate funding needs.
• We’ll now consider how the company’s US$1.20 billion of non-core asset sales and portfolio reshaping affect Healthcare Realty Trust’s investment narrative.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Healthcare Realty Trust Investment Narrative Recap

To own Healthcare Realty Trust, you need to believe its outpatient medical focus and “HR 2.0” overhaul can convert today’s modest profitability into more resilient cash flows, despite recent revenue pressure and an inexperienced leadership bench. The latest results and 2026 EPS guidance keep the near term focused on execution: the key catalyst is realizing operational gains from the revamped platform, while the biggest risk remains that these integration and lease up efforts do not translate into sustainable earnings.

The most relevant update here is the completion of US$1.20 billion of non core asset sales, which simplifies the portfolio and supports the balance sheet at a time when 2026 EPS guidance sits around breakeven. For investors watching the short term, this portfolio reshaping ties directly into the core catalyst of better leasing performance and NOI uplift, but it also sharpens the risk if redeployment and operational improvements fail to offset the income lost from dispositions.

Yet investors should be aware that execution risk around the shift from a transactions oriented culture to an operations oriented one could...

Healthcare Realty Trust's narrative projects $1.2 billion revenue and $275.4 million earnings by 2028.

Uncover how Healthcare Realty Trust's forecasts yield a $19.10 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$19.10 to US$25.42, reflecting a wide band of expectations. Against this, the company’s move to an operations focused model and the associated execution risk highlight why you may want to compare several viewpoints before forming your own view on HR’s future performance.

Explore 2 other fair value estimates on Healthcare Realty Trust - why the stock might be worth just $19.10!

Build Your Own Healthcare Realty Trust Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Healthcare Realty Trust research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Healthcare Realty Trust research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Healthcare Realty Trust's overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.